The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I feasibility study of intraperitoneal cisplatin and intravenous paclitaxel followed by intraperitoneal paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: Gynecologic Oncology Group study 9921.
D. S. Dizon
No relevant relationships to disclose
M. Sill
No relevant relationships to disclose
N. S. Gould
No relevant relationships to disclose
S. C. Rubin
No relevant relationships to disclose
S. D. Yamada
No relevant relationships to disclose
R. DeBernardo
No relevant relationships to disclose
R. S. Mannel
No relevant relationships to disclose
E. L. Eisenhauer
No relevant relationships to disclose
L. R. Duska
No relevant relationships to disclose
P. M. Fracasso
No relevant relationships to disclose